Clinical Trial

A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

Study acronym: GOAL-HF2
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-08.
Trial Details
NCT Number NCT07584967
Lead Sponsor AnaCardio AB
Conditions Heart Failure With Reduced Ejection Fraction (HFrEF)
Enrollment 400 participants
Start Date 2026-09-15
Primary Completion 2028-05-09 (estimated)
Study Completion 2028-06-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-29